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Summary 
Cryptococcus neoformans is an opportunistic fungus that causes life-threatening meningoencephalitis 
in 5-10% of patients with acquired immune deficiency syndrome. Cryptococcal meningoencephalitis 
is characterized by a lymphohistiocytic infiltrate, accumulation of encapsulated forms of C. neo- 
s6rmans, and varying degrees of glial reaction. Little is known about the contribution of endogenous 
central nervous system cells  to the pathogenesis of cryptococcal infections. In this study, we 
investigated the role of astrocytes as potential effector cells against C. neoformans. Primary cultures 
of human fetal astrocytes, activated with interleukin 13 plus interferon 3' inhibited the growth 
of C. neoformans. The inhibition of C. neoformans growth was paralleled by production of nitrite, 
and reversed by the inhibitors of nitric oxide (NO-)  synthase, NG-methyl-mono-arginine and 
NC-nitro-arginine methyl ester.  The results suggest a novel function for human astrocytes in 
host defence and provide a precedent for the use of NO.  as an antimicrobial effector molecule 
by human cells. 
T 
he fungus Cryptococcus  neoformans is most often a pathogen 
for immunosuppressed individuals, and human infections 
almost always involve the brain (1, 2). In the setting of AIDS, 
cryptococcal meningoencephalitis is difficult to treat because 
antifungal drugs  seldom eradicate  the infection (3).  Cell- 
mediated immunity is believed to be the major defence against 
C.  neoformans (4)  with  antibody  (5)  and the complement 
system (6)  providing important opsonins. Human neutro- 
phils, lymphocytes (7, 8), monocytes (9), and alveolar mac- 
rophages (10) have each been reported to mediate antifungal 
activity in vitro. Some human effector cells,  including NK 
cells, have been shown to require antibody for anticryptococcal 
activity (11). In contrast to rodent macrophages which exert 
antifungal activities through nitric oxide (NO.)-mediated 
mechanisms (12), the mechanisms by which human effector 
cells mediate antifungal activity are not well characterized. 
The pathogenesis of central nervous system (CNS) infec- 
tion by C. neoformans is poorly understood, but it is likely 
that local immunity is important in limiting the infection 
in the brain. Recent studies of mouse intracerebral injection 
models have suggested that CNS phagocytic mechanisms may 
be important in limiting cryptococcal infection (13).  Simi- 
larly, human microglial cells avidly phagocytose C. neoformans 
in the presence of specific antibody and mediate fungistasis 
independent of NO. production (Lee, S. C., and A. CasadevaU, 
unpublished observations).  The purpose of this study was 
to examine the role of the astrocyte as a potential anticryp- 
tococcal effector cell. 
CNS tissue is characterized by an extensive neuroglial net- 
work; astrocytes are ubiquitous in the brain (14,  15). In the 
subpial and perivascular zone, a specialized barrier formed 
by astrocytes (glia limitans) separates CNS parenchyma from 
subarachnoid space (14,  15) (see Fig.  1). The glia limitans 
is composed in part by basement membrane produced by as- 
trocytes and permeable to diffusible molecules such as NO. 
or cytokines. Astrocytes are immunocompetent cells that can 
express immune molecules, present antigen, produce cytokines, 
and express activities of NO.  synthase (NOS)  (14,  16-19). 
Therefore we entertained the possibility that astrocytes could 
mediate antifungal activity by virtue of their capacity to pro- 
duce soluble effector molecules, including NO.. 
Materials and Methods 
Astrocyte Culture.  Astrocyte cultures were prepared from second 
trimester human fetal abortuses, as previously described (19). The 
purity of astrocytes was achieved  by repeated trypsinization of mixed 
cultures and final cultures consisted of >99% glial fibrillary acidic 
protein-positive cells. Astrocytes seeded in 96-well, flat-bottom tissue 
culture plates at 104 cells per well in DMEM/10% heat-inactivated 
FCS were grown to reach confluence at 37~  in 5% CO2 (esti- 
mated final cell density was 20,000 cells per well). 
Cell Stimulation and r-~H]leucine Incorporation.  Cultures were 
then stimulated with 200 U/ml each of recombinant human IL-13 
(gift of Dr. C. Reynolds, National Cancer Institute, Frederick, MD) 
and IFN-3/(Genzyme Corp., Cambridge, MA), or grown with 
medium alone (control).  24 h later, C. neoformans (strain 24067, 
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ville, MD) cells at varying numbers were added resulting in approxi- 
mate E/T ratios of 20:1, 40:1, and 80:1, and the cultures were further 
incubated for 24 h at 37~  Astrocyte cultures were pulsed with 
1 #Ci of r-[3H]leucine  (Amersham, Arlington Heights, IL; sp act, 
150 Ci/mmol) per well 24 h after the challenge with C. neoformans. 
The cultures were incubated for an additional  24 h and C  neoformans- 
incorporated [3H]leucine  was determined by measurement of cpm 
using an automated cell harvester and liquid scintillation counter. 
This method was adapted from previously published protocols (20) 
with minor modifications. There was a good correlation between 
cpm and the number of C.  neoformans added, even with the low 
yeast numbers used (data not shown). The background cpm values 
in  astrocyte cultures  without  C.  neoformans were <~300 (cpm in 
cytokine activated cultures were less than or equal to control astro- 
cyte cultures),  and these values were subtracted from the cpm values 
of experimental wells. 
CFUAssay.  Human fetal astrocytes were prepared and stimu- 
lated as described above, except that 24 h after the addition of fungi, 
the incubation was terminated and the number of viable fungi was 
determined by CFU assay. A companion set of cultures was pre- 
pared in which NC-methyl-mono-arginine (NMMA) or N~  - 
arginine  methyl  ester  (NAME)  (200  #M  final  concentrations; 
Sigma Chemical  Co.,  St.  Louis,  MO)  were  added  along  with 
cytokines. Cytokine- and/or drug-treated cultures were challenged 
with C. neoformans 24 h  later at the E/T ratio of 20:1, 40:1,  and 
80:1. For the CFU assay, supernatants and the cell lysates, prepared 
by the addition of distilled water, were combined, and serial dilu- 
tions of organisms in each well were plated on Sabouraud dextrose 
agar. The colonies were counted after 48 h of incubation at 30~ 
Results 
Two methods were used to study the effect of astrocytes 
on C. neoformans growth,  determination of CFUs and [3H]- 
leucine incorporation (20). CFU determination measures the 
number  of viable yeast  cells  after  24-h  coincubation  with 
astrocytes.  [3H]leucine incorporation,  on the other hand, re- 
flects growth of yeast surviving 48-h coincubation with as- 
trocytes (20).  Both methodologies  showed that  IL-13 plus 
IFN-7 activated astrocytes inhibited  fungal growth.  Inhibi- 
tion of s  growth by cytokine-activated  astrocytes was 
demonstrated  in  six separate experiments.  Fig.  2  illustrates 
results obtained using  [3H]leucine incorporation  as an indi- 
cator of fungal growth. At effector (astrocyte) to target (cryp- 
tococcus) ratios of 20:1-80:1,  there was a 10-70% reduction 
in  [3H]leucine  incorporation  for C.  neoformans  cells  in  the 
presence of cytokine-activated astrocytes relative to control, 
nonactivated astrocytes. The effect was greatest at the higher 
E/T ratios.  The differences in fungal growth between wells 
containing  activated  and  nonactivated  astrocytes  could  be 
readily detected visually by microscopic examination  of the 
culture at 24 and 48 h.  As shown in Fig.  3, in the presence 
Figure  1.  A section  from a human case ofcryptococcal  meningitis stained 
for glial fibrillary acidic protein  (GFAP), an astrocyte-specific  protein, 
showing proximity of GFAP-positive  subpial astrocytes and C. neoformans 
(arrows). Hematoxylin-eosin  counterstain (Nomarski optics). Astrocyte  foot 
processes abut the subarachnoid space  that contains inflammatory cells and 
C. neoformans. 
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Activated human astrocytes  limit the proliferation of C. neo- 
formans as measured by [3H]leucine incorporation.  Astrocytes plated at 
20,000 cells  per well in 96-well microtiter wells were grown with medium 
only (control) or with 200 U/ml rhlL-13 and IFN-% 24 h later, C. neo- 
formans at various numbers (or indicated E/T ratios) were added to cul- 
tures in four replicate wells and further grown for 48 h before harvest. 
r-[3H]leucine at 1 #Ci per well was present for the last 24 h of culture. 
Counts per minute was calculated for each well as described in Materials 
and Methods. Values shown are the mean and standard deviation of four 
replicate wells. Data represent  one of  four similar  experiments. (*) Significant 
differences (p <0.05) compared with controls (Student's t test). 
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formans and  human astrocyte  in coculture.  (a) 
C.  neoformans  grow  over  control  astrocyte 
monolayer in dumps or dispersed  single organisms. 
Highly refractile, variably sized budding yeast are 
present in multiple planes of focus (arrowhead).  (b) 
Marked reduction in C. neoformans growth is ob- 
served in cytokine-treated astrocyte cultures (arrow- 
head). After IL-1/~  plus IFNw treatment, astrocytes 
develop processes (17). 
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Figure 4.  t-arginine analogs inhibit the cytokine-mediated human as- 
trocyte anticryptococcal activity. Astrocytes were prepared and stimulated 
as described  in the legend to Fig. 2, except this time parallel  sets of cytokine- 
of"resting astrocytes" C. neoformans grew extraceUularly;  no 
yeast cells were apparently internalized.  In contrast,  fungal 
growth was significantly reduced in cytokine-activated astro- 
cyte cultures.  Fig.  4  shows a 24-h  CFU assay done at  the 
same E/T ratios as in Fig. 2. There was a 52-64% inhibition 
of C. neoformans CFU in the presence of cytokine-activated 
astrocytes relative  to nonactivated  astrocytes. 
Measurement  of nitrite  production  in  parallel  astrocyte 
cultures revealed nitrite levels of 10  _+  1.0/~M in astrocyte 
cultures stimulated with cytokines compared with controls 
stimulated astrocytes  were also treated with 200/~M of NMMA or NAME. 
After 24 h of coculture with C. neoformans  at various E/T ratios, cultures 
were terminated and CFUs were determined as described in Materials and 
Methods. Values shown are the mean and standard deviation of four repli- 
cate wells. Data represent one of two similar experiments.  (*) Denote 
significant differences ~  <0.005) compared with controls (Student's t test). 
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tivity for assay). To demonstrate more directly the involve- 
ment of NO--mediated mechanisms in the antifungal effect, 
the 1.-arginine analogues, NMMA and NAME, were studied 
for their ability to inhibit the anticryptococcal activity of 
cytokine-stimulated astrocyte cultures. Fig. 4 shows that the 
addition of either inhibitor at a concentration of 200 #M 
completely inhibited the anticryptococcal activity of cytokine- 
activated astrocyte cultures. Nitrite levels measured in par- 
allel wells demonstrated an 85 and 70% inhibition of nitrite 
production by NMMA and NAME, respectively, similar to 
the degree of inhibition reported by us (17) and others (21) 
at this concentration of inhibitors.  Addition of IL-13 and 
IFN-3: alone or in combination without astrocytes, did not 
exert antifungal activity (data not shown). 
Discussion 
Two lines of evidence implicate NO. as the effector mole- 
cule in the astrocyte mediated inhibition  of C.  neoformans 
growth shown in this study: (a) nitrite, a byproduct of NO. 
synthase activity, was present only in cytokine-activated as- 
trocytes cultures and its presence was associated with fungal 
growth inhibition; and (b) the I:arginine analogues NMMA 
and NAME completely abolished the antifungal effect of 
cytokine-activated astrocytes. 
The magnitude of in vitro antifungal effects observed for 
cytokine-treated astrocytes is similar to that reported for other 
effector cells, such as macrophages (9), lymphocytes (7), and 
NK cells (11). The E/T ratios at which astrocytes were shown 
to exert anticryptococcal activity were also comparable with 
E/T ratios at which peripheral immune cells have been shown 
to exhibit anticryptococcal activity (7,  9,  11). 
NO. and its derivatives have been shown to be important 
mediators of antifungal activity by murine macrophages (12, 
22)  and to directly inhibit C.  neoformans in vitro (23).  In 
contrast to mice, human mononuclear phagocytes, including 
microglia, have no convincing inducible NOS activity (17, 21), 
making it unlikely that NO.  is an antimicrobial molecule 
used by human phagocytic cells. On the other hand, evidence 
presented here that activated astrocytes inhibit C. neoformans 
growth in part at least through NO.-mediated mechanism 
opens the possibility that similar antimicrobial mechanisms 
may be operant in vivo. A complex interactive network may 
exist among the various brain cell types to provide a coordi- 
nated local defense to infection. For example, microglia are 
eflicient phagocytic cells that produce IL-13 (18), which is 
a potent inducer of nitrite synthesis by astrocytes (17). IFN-% 
a T cell cytokine, in turn, provides an additional signal for 
nitrite production by astrocytes (17). 
In  human infection,  preliminary data suggest  that  the 
number of cryptococci in brain tissue is inversely correlated 
with the number of infiltrating inflammatory cells, including 
lymphocytes (Lee, S. C., unpublished observations). Cryp- 
tococcal meningoencephalitis in patients with AIDS often 
involves  the accumulation of yeast in the brain with little 
inflammation or glial activation (2). These cases may reflect 
a lack of proper signals  for astrocyte activation. 
The results of this study demonstrate that activated astro- 
cytes can inhibit C. neoformans growth in vitro and strongly 
implicate NO. as an antifungal effector molecule in humans. 
The close proximity of astrocytes and C. neoformans cells in 
human cryptococcal meningoencephalitis suggests a novel role 
of activated astrocytes as antimicrobial effector cells. Ther- 
apeutic strategies directed at enhancing astrocyte activation 
may be useful in the therapy of human cryptococcosis. 
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